The global Insulin Delivery Devices Market was valued at USD 30.9 billion in 2022 and is expected to grow significantly, ...

Third-quarter results for Medtronic (NYSE:MDT) included a timeline for a planned label expansion for its automated insulin ...

Ladenburg analyst Jeffrey Cohen initiated coverage of Beta Bionics (BBNX) with a Buy rating and $31 price target The medical device company ...

Medtronic posted a strong profit for Q3 of fiscal year 2025, though shares were down as its cardiac ablation product success ...

By Phil Galewitz for KFF Health News. Broadcast version by Trimmel Gomes for Florida News Connection reporting for the KFF Health News-Public News Service Collaboration Just a few years ago, children ...

Lilly has taken a non-exclusive license to deploy Dexcom’s CGM systems – which include app-based remote monitoring and alarm functions – in pen- and pump-based insulin systems that form the ...

In this instance, the partnership will combine Senseonics’ Eversense continuous glucose monitor (CGM), TypeZero’s InControl algorithms, and Roche’s Accu-Chek Insight Insulin Pump.

Medtronic's stock has been static, not delivering any gains for investors. Click here to find out why MDT stock is a Buy.

We recently compiled a list of the 12 Best Internet of Things Stocks To Buy According to Analysts. In this article, we are going to take a look at where DexCom, Inc.

Some monitors also may be combined with an insulin pump. Other CGM devices include user-friendly, cloud-based reporting software. When blood glucose information is received by a smart device, it is ...